What is the starting dose of Strattera (atomoxetine) for an 11-year-old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Atomoxetine (Strattera) for an 11-Year-Old Child

For an 11-year-old child, atomoxetine (Strattera) should be initiated at a total daily dose of approximately 0.5 mg/kg/day and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg/day. 1

Initial Dosing Guidelines

  • Atomoxetine should be started at 0.5 mg/kg/day for children weighing up to 70 kg 1
  • The medication can be administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening 1
  • After a minimum of 3 days at the starting dose, the dose can be increased to the target dose of approximately 1.2 mg/kg/day 1, 2
  • No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day 1

Maximum Dosing Considerations

  • The total daily dose in children should not exceed 1.4 mg/kg or 100 mg, whichever is less 1
  • For children who are poor CYP2D6 metabolizers or taking strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine), atomoxetine should be initiated at 0.5 mg/kg/day and only increased to the usual target dose if symptoms fail to improve after 4 weeks and the initial dose is well tolerated 1

Administration Recommendations

  • Atomoxetine can be taken with or without food, although taking it with food may improve gastrointestinal tolerability 1
  • The capsules should be taken whole and are not intended to be opened 1
  • The medication can be discontinued without being tapered 1

Efficacy Considerations

  • Clinical trials have demonstrated that atomoxetine at 1.2 mg/kg/day is effective for treating ADHD symptoms in children 3
  • A graded dose-response has been observed, with 1.2 mg/kg/day showing similar efficacy to 1.8 mg/kg/day, suggesting that 1.2 mg/kg/day is an appropriate initial target dose for most patients 3

Safety Monitoring

  • Patients should be monitored closely for suicidality, clinical worsening, and unusual changes in behavior, especially during the first few months of treatment or at times of dose changes 2
  • Common adverse effects include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence 2, 4
  • Prior to initiating treatment, patients should be screened for a personal or family history of bipolar disorder, mania, or hypomania 1

Clinical Pearls

  • Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics 4, 5
  • Unlike stimulant medications, atomoxetine has a negligible risk of abuse or misuse and is not a controlled substance in the US 4, 5
  • The full therapeutic effect may not be evident until 2-4 weeks of treatment at the target dose 4
  • The duration of action extends throughout the waking hours, and the drug effects may persist up to the next morning with a single morning dose 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.